<!DOCTYPE html>
<html lang="en" dir="auto">

<head>
<head>
    <title>cardiovascular medicine</title>
    <meta charset="utf-8">
    <meta name="description"
        content="Website meta description for google search results go here" />
    <meta name="dc.relation" content="https://trxiv.yorks0n.com" />
    <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
    <meta name="theme-color" content="#1A94D2" />

    

    
    
    
    <link rel="stylesheet" href="/css/main.min.css" media="screen">

</head>


<meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<meta name="robots" content="index, follow">
<title>cardiovascular medicine | TRxiv2</title>
<meta name="keywords" content="">
<meta name="description" content="Cardiovascular risk prediction using metabolomic biomarkers and polygenic risk scores: A cohort study and modelling analyses
Authors: Ritchie, S. C.; Jiang, X.; Pennells, L.; Xu, Y.; Coffey, C.; Liu, Y.; Surendran, P.; Karthikeyan, S.; Lambert, S. A.; Danesh, J.; Butterworth, A. S.; Wood, A.; Kaptoge, S.; Di Angelantonio, E.; Inouye, M.
Score: 27.9, Published: 2023-11-01 DOI: 10.1101/2023.10.31.23297859
Metabolomic platforms using nuclear magnetic resonance (NMR) spectroscopy can now rapidly quantify many circulating metabolites which are potential biomarkers of cardiovascular disease (CVD).">
<meta name="author" content="">
<link rel="canonical" href="https://trxiv.yorks0n.com/posts/cardiovascular-medicine/">
<link crossorigin="anonymous" href="/assets/css/stylesheet.904bd1e751cdd2a584fa6bed3fa1166dfd8ec9949ebfd0c4d69c5add5e17c23d.css" integrity="sha256-kEvR51HN0qWE&#43;mvtP6EWbf2OyZSev9DE1pxa3V4Xwj0=" rel="preload stylesheet" as="style">
<script defer crossorigin="anonymous" src="/assets/js/highlight.f413e19d0714851f6474e7ee9632408e58ac146fbdbe62747134bea2fa3415e0.js" integrity="sha256-9BPhnQcUhR9kdOfuljJAjlisFG&#43;9vmJ0cTS&#43;ovo0FeA="
    onload="hljs.initHighlightingOnLoad();"></script>
<link rel="icon" href="https://trxiv.yorks0n.com/favicon.ico">
<link rel="icon" type="image/png" sizes="16x16" href="https://trxiv.yorks0n.com/favicon-16x16.png">
<link rel="icon" type="image/png" sizes="32x32" href="https://trxiv.yorks0n.com/favicon-32x32.png">
<link rel="apple-touch-icon" href="https://trxiv.yorks0n.com/apple-touch-icon.png">
<link rel="mask-icon" href="https://trxiv.yorks0n.com/safari-pinned-tab.svg">
<meta name="theme-color" content="#2e2e33">
<meta name="msapplication-TileColor" content="#2e2e33">
<noscript>
    <style>
        #theme-toggle,
        .top-link {
            display: none;
        }

    </style>
    <style>
        @media (prefers-color-scheme: dark) {
            :root {
                --theme: rgb(29, 30, 32);
                --entry: rgb(46, 46, 51);
                --primary: rgb(218, 218, 219);
                --secondary: rgb(155, 156, 157);
                --tertiary: rgb(65, 66, 68);
                --content: rgb(196, 196, 197);
                --hljs-bg: rgb(46, 46, 51);
                --code-bg: rgb(55, 56, 62);
                --border: rgb(51, 51, 51);
            }

            .list {
                background: var(--theme);
            }

            .list:not(.dark)::-webkit-scrollbar-track {
                background: 0 0;
            }

            .list:not(.dark)::-webkit-scrollbar-thumb {
                border-color: var(--theme);
            }
        }

    </style>
</noscript><meta property="og:title" content="cardiovascular medicine" />
<meta property="og:description" content="Cardiovascular risk prediction using metabolomic biomarkers and polygenic risk scores: A cohort study and modelling analyses
Authors: Ritchie, S. C.; Jiang, X.; Pennells, L.; Xu, Y.; Coffey, C.; Liu, Y.; Surendran, P.; Karthikeyan, S.; Lambert, S. A.; Danesh, J.; Butterworth, A. S.; Wood, A.; Kaptoge, S.; Di Angelantonio, E.; Inouye, M.
Score: 27.9, Published: 2023-11-01 DOI: 10.1101/2023.10.31.23297859
Metabolomic platforms using nuclear magnetic resonance (NMR) spectroscopy can now rapidly quantify many circulating metabolites which are potential biomarkers of cardiovascular disease (CVD)." />
<meta property="og:type" content="article" />
<meta property="og:url" content="https://trxiv.yorks0n.com/posts/cardiovascular-medicine/" /><meta property="article:section" content="posts" />
<meta property="article:published_time" content="2023-11-19T10:38:34+00:00" />
<meta property="article:modified_time" content="2023-11-19T10:38:34+00:00" />

<meta name="twitter:card" content="summary"/>
<meta name="twitter:title" content="cardiovascular medicine"/>
<meta name="twitter:description" content="Cardiovascular risk prediction using metabolomic biomarkers and polygenic risk scores: A cohort study and modelling analyses
Authors: Ritchie, S. C.; Jiang, X.; Pennells, L.; Xu, Y.; Coffey, C.; Liu, Y.; Surendran, P.; Karthikeyan, S.; Lambert, S. A.; Danesh, J.; Butterworth, A. S.; Wood, A.; Kaptoge, S.; Di Angelantonio, E.; Inouye, M.
Score: 27.9, Published: 2023-11-01 DOI: 10.1101/2023.10.31.23297859
Metabolomic platforms using nuclear magnetic resonance (NMR) spectroscopy can now rapidly quantify many circulating metabolites which are potential biomarkers of cardiovascular disease (CVD)."/>


<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "BreadcrumbList",
  "itemListElement": [, 
    {
      "@type": "ListItem",
      "position":  2 ,
      "name": "Posts",
      "item": "https://trxiv.yorks0n.com/posts/"
    }, 
    {
      "@type": "ListItem",
      "position":  3 ,
      "name": "cardiovascular medicine",
      "item": "https://trxiv.yorks0n.com/posts/cardiovascular-medicine/"
    }
  ]
}
</script>
<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "BlogPosting",
  "headline": "cardiovascular medicine",
  "name": "cardiovascular medicine",
  "description": "Cardiovascular risk prediction using metabolomic biomarkers and polygenic risk scores: A cohort study and modelling analyses\nAuthors: Ritchie, S. C.; Jiang, X.; Pennells, L.; Xu, Y.; Coffey, C.; Liu, Y.; Surendran, P.; Karthikeyan, S.; Lambert, S. A.; Danesh, J.; Butterworth, A. S.; Wood, A.; Kaptoge, S.; Di Angelantonio, E.; Inouye, M.\nScore: 27.9, Published: 2023-11-01 DOI: 10.1101/2023.10.31.23297859\nMetabolomic platforms using nuclear magnetic resonance (NMR) spectroscopy can now rapidly quantify many circulating metabolites which are potential biomarkers of cardiovascular disease (CVD).",
  "keywords": [
    
  ],
  "articleBody": " Cardiovascular risk prediction using metabolomic biomarkers and polygenic risk scores: A cohort study and modelling analyses\nAuthors: Ritchie, S. C.; Jiang, X.; Pennells, L.; Xu, Y.; Coffey, C.; Liu, Y.; Surendran, P.; Karthikeyan, S.; Lambert, S. A.; Danesh, J.; Butterworth, A. S.; Wood, A.; Kaptoge, S.; Di Angelantonio, E.; Inouye, M.\nScore: 27.9, Published: 2023-11-01 DOI: 10.1101/2023.10.31.23297859\nMetabolomic platforms using nuclear magnetic resonance (NMR) spectroscopy can now rapidly quantify many circulating metabolites which are potential biomarkers of cardiovascular disease (CVD). Here, we analyse [~]170,000 UK Biobank participants (5,096 incident CVD cases) without a history of CVD and not on lipid-lowering treatments to evaluate the potential for improving 10-year CVD risk prediction using NMR biomarkers in addition to conventional risk factors and polygenic risk scores (PRSs). Using machine learning, we developed sex-specific NMR scores for coronary heart disease (CHD) and ischaemic stroke, then estimated their incremental improvement of 10-year CVD risk prediction when added to guideline-recommended risk prediction models (i.e., SCORE2) with and without PRSs. The risk discrimination provided by SCORE2 (Harrells C-index = 0.718) was similarly improved by addition of NMR scores ({Delta}C-index 0.011; 0.009, 0.014) and PRSs ({Delta}C-index 0.009; 95% CI: 0.007, 0.012), which offered largely orthogonal information. Addition of both NMR scores and PRSs yielded the largest improvement in C-index over SCORE2, from 0.718 to 0.737 ({Delta}C-index 0.019; 95% CI: 0.016, 0.022). Concomitant improvements in risk stratification were observed in categorical net reclassification index when using guidelines-recommended risk categorisation, with net case reclassification of 13.04% (95% CI: 11.67%, 14.41%) when adding both NMR scores and PRSs to SCORE2. Using population modelling, we estimated that targeted risk-reclassification with NMR scores and PRSs together could increase the number of CVD events prevented per 100,000 screened from 201 to 370 ({Delta}CVDprevented: 170; 95% CI: 158, 182) while essentially maintaining the number of statins prescribed per CVD event prevented. Overall, we show combining NMR scores and PRSs with SCORE2 moderately enhances prediction of first-onset CVD, and could have substantial population health benefit if applied at scale.\nCardiovascular and Neurological Outcomes in Patients Treated with Edoxaban for Atrial Fibrillation and Characteristics in Patients with Cancer\nAuthors: Cheng, K.-H.; Tu, H.-P.; Cheng, K.-C.; Scherrer-Crosbie, M.; Hsu, T.-Y.\nScore: 9.8, Published: 2023-10-26 DOI: 10.1101/2023.10.25.23297577\nBACKGROUNDDirect oral anticoagulants (DOACs) outperform warfarin in vascular and bleeding events in atrial fibrillation (AF) patients. Yet, effects of DOACs on congestive heart failure (CHF) and Alzheimers disease (AD) remain less explored. METHODSUsing the Taiwan National Health Insurance Research Database, a nationwide retrospective cohort study was conducted. The study matched 5,683 non-valvular atrial fibrillation (NVAF) edoxaban patients with 11,366 warfarin patients, and 703 NVAF with cancer (NVAF-C) edoxaban patients with 1,406 warfarin patients. Vasular and non-vascular outcomes, with focuses on CHF and AD, were compared between the edoxaban and warfarin users. RESULTSEdoxaban significantly lowered adjusted hazrad ratio (aHR) of all-cause mortality, hospitalization for gastrointestinal bleeding, and CHF (0.37, 0.74, and 0.26, respectively, in NVAF; 0.39, 0.67, and 0.31, respectively, in NVAF-C, all p \u003c 0.05), compared to warfarin. Edoxaban was associated with significantly lower aHRs of acute myocardial infarction, peripheral artery disease, venous thromboembolism, pulmonary embolism, and AD (0.71, 0.48, 0.55, 0.20, and 0.66, respectively; all p \u003c 0.05) in NVAF patients versus warfarin. However, edoxaban had higher aHR of hospitalized bleeding (1.19, p = 0.002) than warfarin in NVAF patients, but not in NVAF-C patients. CONCLUSIONSEdoxaban demonstrated lowered CHF risks in both NVAF and NVAF-C patients, and reduced AD occurrence in NVAF patients versus warfarin. These findings advocate for edoxabans use in AF cases. CLINICAL PERSPECTIVEO_ST_ABSWhat Is New?C_ST_ABSThe study reveals that in patients with atrial fibrillation (AF), edoxaban, a direct oral anticoagulant (DOAC), demonstrates significant advantages over warfarin. Notably, edoxaban is associated with a reduced risk of congestive heart failure (CHF) and Alzheimers disease (AD) when compared to warfarin. Clinical Implications?These findings have important clinical implications. Edoxaban appears to be a superior anticoagulant choice for AF patients, as it lowers the risk of CHF and AD. This highlights the potential of edoxaban to improve patient outcomes and underscores its relevance for managing AF cases.\nSomatic RIT1 indels identified in arteriovenous malformations hyperactivate RAS-MAPK signaling and are amenable to MEK inhibition\nAuthors: Kapp, F. G.; Bazgir, F.; Mahammadzade, N.; Vassella, E.; Doring, Y.; Holm, A.; Karow, A.; Seebauer, C.; Platz Batista da Silva, N.; Wohlgemuth, W. A.; Kroning, P.; Niemeyer, C. M.; Schanze, D.; Zenker, M.; Eng, W.; Ahmadian, M. R.; Baumgartner, I.; Roessler, J.\nScore: 1.8, Published: 2023-11-13 DOI: 10.1101/2023.11.13.23298448\nArteriovenous malformations (AVM) are benign vascular anomalies prone to pain, bleeding, and progressive growth. Treatment is often difficult and relapse after therapy is common. AVM are mainly caused by somatic mosaicism with pathogenic variants of the RAS-MAPK pathway. However, a causative variant is not identified in all patients. Using ultra-deep next generation sequencing we identified novel somatic RIT1 indel variants in lesional tissue of three AVM patients. RIT1 - not previously implicated in AVM development - encodes a RAS-like protein that can modulate RAS-MAPK signaling. For biochemical characterization, we expressed RIT1 variants in HEK293T cells, which led to a strong increase in ERK1/2 phosphorylation. Endothelial-specific mosaic overexpression of the RIT1 indels in zebrafish embryos induced AVM formation, highlighting the functional importance in vascular development. Both ERK1/2 hyperactivation in vitro and AVM formation in vivo could be suppressed by pharmacological MEK inhibition. Targeted treatment with the MEK inhibitor trametinib led to a significant decrease in bleeding episodes and AVM size in one patient. Our findings expand the genetic spectrum of AVM by identifying RIT1 as a novel gene involved in AVM formation and pave the way for targeted treatment and clinical trials in patients with AVM.\n",
  "wordCount" : "935",
  "inLanguage": "en",
  "datePublished": "2023-11-19T10:38:34Z",
  "dateModified": "2023-11-19T10:38:34Z",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://trxiv.yorks0n.com/posts/cardiovascular-medicine/"
  },
  "publisher": {
    "@type": "Organization",
    "name": "TRxiv2",
    "logo": {
      "@type": "ImageObject",
      "url": "https://trxiv.yorks0n.com/favicon.ico"
    }
  }
}
</script>
</head>

<body class="" id="top">
<script>
    if (localStorage.getItem("pref-theme") === "dark") {
        document.body.classList.add('dark');
    } else if (localStorage.getItem("pref-theme") === "light") {
        document.body.classList.remove('dark')
    } else if (window.matchMedia('(prefers-color-scheme: dark)').matches) {
        document.body.classList.add('dark');
    }

</script>

<header class="header">
    <nav class="nav">
        <div class="logo">
            <a href="https://trxiv.yorks0n.com" accesskey="h" title="TRxiv2 (Alt + H)">TRxiv2</a>
            <div class="logo-switches">
                <button id="theme-toggle" accesskey="t" title="(Alt + T)">
                    <svg id="moon" xmlns="http://www.w3.org/2000/svg" width="24" height="18" viewBox="0 0 24 24"
                        fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round"
                        stroke-linejoin="round">
                        <path d="M21 12.79A9 9 0 1 1 11.21 3 7 7 0 0 0 21 12.79z"></path>
                    </svg>
                    <svg id="sun" xmlns="http://www.w3.org/2000/svg" width="24" height="18" viewBox="0 0 24 24"
                        fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round"
                        stroke-linejoin="round">
                        <circle cx="12" cy="12" r="5"></circle>
                        <line x1="12" y1="1" x2="12" y2="3"></line>
                        <line x1="12" y1="21" x2="12" y2="23"></line>
                        <line x1="4.22" y1="4.22" x2="5.64" y2="5.64"></line>
                        <line x1="18.36" y1="18.36" x2="19.78" y2="19.78"></line>
                        <line x1="1" y1="12" x2="3" y2="12"></line>
                        <line x1="21" y1="12" x2="23" y2="12"></line>
                        <line x1="4.22" y1="19.78" x2="5.64" y2="18.36"></line>
                        <line x1="18.36" y1="5.64" x2="19.78" y2="4.22"></line>
                    </svg>
                </button>
            </div>
        </div>
        <ul id="menu">
        </ul>
    </nav>
</header>
<main class="main">
<article class="post-single">
  <header class="post-header">
    
    <h1 class="post-title">
      cardiovascular medicine
    </h1>
    <div class="post-meta">&lt;span&gt;updated on November 19, 2023&lt;/span&gt;

</div>
  </header> 
  <div class="post-content"><div class="accordion accordion-flush" id="accordionFlushExample"><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.10.31.23297859">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.10.31.23297859" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.10.31.23297859">
        <p class="paperTitle">Cardiovascular risk prediction using metabolomic biomarkers and polygenic risk scores: A cohort study and modelling analyses</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.10.31.23297859" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.10.31.23297859" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Ritchie, S. C.; Jiang, X.; Pennells, L.; Xu, Y.; Coffey, C.; Liu, Y.; Surendran, P.; Karthikeyan, S.; Lambert, S. A.; Danesh, J.; Butterworth, A. S.; Wood, A.; Kaptoge, S.; Di Angelantonio, E.; Inouye, M.</p>
        <p class="info">Score: 27.9, Published: 2023-11-01 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.10.31.23297859' target='https://doi.org/10.1101/2023.10.31.23297859'> 10.1101/2023.10.31.23297859</a></p>
        <p class="abstract">Metabolomic platforms using nuclear magnetic resonance (NMR) spectroscopy can now rapidly quantify many circulating metabolites which are potential biomarkers of cardiovascular disease (CVD). Here, we analyse [~]170,000 UK Biobank participants (5,096 incident CVD cases) without a history of CVD and not on lipid-lowering treatments to evaluate the potential for improving 10-year CVD risk prediction using NMR biomarkers in addition to conventional risk factors and polygenic risk scores (PRSs). Using machine learning, we developed sex-specific NMR scores for coronary heart disease (CHD) and ischaemic stroke, then estimated their incremental improvement of 10-year CVD risk prediction when added to guideline-recommended risk prediction models (i.e., SCORE2) with and without PRSs. The risk discrimination provided by SCORE2 (Harrells C-index = 0.718) was similarly improved by addition of NMR scores ({Delta}C-index 0.011; 0.009, 0.014) and PRSs ({Delta}C-index 0.009; 95% CI: 0.007, 0.012), which offered largely orthogonal information. Addition of both NMR scores and PRSs yielded the largest improvement in C-index over SCORE2, from 0.718 to 0.737 ({Delta}C-index 0.019; 95% CI: 0.016, 0.022). Concomitant improvements in risk stratification were observed in categorical net reclassification index when using guidelines-recommended risk categorisation, with net case reclassification of 13.04% (95% CI: 11.67%, 14.41%) when adding both NMR scores and PRSs to SCORE2. Using population modelling, we estimated that targeted risk-reclassification with NMR scores and PRSs together could increase the number of CVD events prevented per 100,000 screened from 201 to 370 ({Delta}CVDprevented: 170; 95% CI: 158, 182) while essentially maintaining the number of statins prescribed per CVD event prevented. Overall, we show combining NMR scores and PRSs with SCORE2 moderately enhances prediction of first-onset CVD, and could have substantial population health benefit if applied at scale.</p>
      </div>
    </div>
  </div><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.10.25.23297577">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.10.25.23297577" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.10.25.23297577">
        <p class="paperTitle">Cardiovascular and Neurological Outcomes in Patients Treated with Edoxaban for Atrial Fibrillation and Characteristics in Patients with Cancer</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.10.25.23297577" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.10.25.23297577" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Cheng, K.-H.; Tu, H.-P.; Cheng, K.-C.; Scherrer-Crosbie, M.; Hsu, T.-Y.</p>
        <p class="info">Score: 9.8, Published: 2023-10-26 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.10.25.23297577' target='https://doi.org/10.1101/2023.10.25.23297577'> 10.1101/2023.10.25.23297577</a></p>
        <p class="abstract">BACKGROUNDDirect oral anticoagulants (DOACs) outperform warfarin in vascular and bleeding events in atrial fibrillation (AF) patients. Yet, effects of DOACs on congestive heart failure (CHF) and Alzheimers disease (AD) remain less explored.

METHODSUsing the Taiwan National Health Insurance Research Database, a nationwide retrospective cohort study was conducted. The study matched 5,683 non-valvular atrial fibrillation (NVAF) edoxaban patients with 11,366 warfarin patients, and 703 NVAF with cancer (NVAF-C) edoxaban patients with 1,406 warfarin patients. Vasular and non-vascular outcomes, with focuses on CHF and AD, were compared between the edoxaban and warfarin users.

RESULTSEdoxaban significantly lowered adjusted hazrad ratio (aHR) of all-cause mortality, hospitalization for gastrointestinal bleeding, and CHF (0.37, 0.74, and 0.26, respectively, in NVAF; 0.39, 0.67, and 0.31, respectively, in NVAF-C, all p &lt; 0.05), compared to warfarin. Edoxaban was associated with significantly lower aHRs of acute myocardial infarction, peripheral artery disease, venous thromboembolism, pulmonary embolism, and AD (0.71, 0.48, 0.55, 0.20, and 0.66, respectively; all p &lt; 0.05) in NVAF patients versus warfarin. However, edoxaban had higher aHR of hospitalized bleeding (1.19, p = 0.002) than warfarin in NVAF patients, but not in NVAF-C patients.

CONCLUSIONSEdoxaban demonstrated lowered CHF risks in both NVAF and NVAF-C patients, and reduced AD occurrence in NVAF patients versus warfarin. These findings advocate for edoxabans use in AF cases.

CLINICAL PERSPECTIVEO_ST_ABSWhat Is New?C_ST_ABSThe study reveals that in patients with atrial fibrillation (AF), edoxaban, a direct oral anticoagulant (DOAC), demonstrates significant advantages over warfarin. Notably, edoxaban is associated with a reduced risk of congestive heart failure (CHF) and Alzheimers disease (AD) when compared to warfarin.

Clinical Implications?These findings have important clinical implications. Edoxaban appears to be a superior anticoagulant choice for AF patients, as it lowers the risk of CHF and AD. This highlights the potential of edoxaban to improve patient outcomes and underscores its relevance for managing AF cases.</p>
      </div>
    </div>
  </div><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.11.13.23298448">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.11.13.23298448" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.11.13.23298448">
        <p class="paperTitle">Somatic RIT1 indels identified in arteriovenous malformations hyperactivate RAS-MAPK signaling and are amenable to MEK inhibition</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.11.13.23298448" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.11.13.23298448" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Kapp, F. G.; Bazgir, F.; Mahammadzade, N.; Vassella, E.; Doring, Y.; Holm, A.; Karow, A.; Seebauer, C.; Platz Batista da Silva, N.; Wohlgemuth, W. A.; Kroning, P.; Niemeyer, C. M.; Schanze, D.; Zenker, M.; Eng, W.; Ahmadian, M. R.; Baumgartner, I.; Roessler, J.</p>
        <p class="info">Score: 1.8, Published: 2023-11-13 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.11.13.23298448' target='https://doi.org/10.1101/2023.11.13.23298448'> 10.1101/2023.11.13.23298448</a></p>
        <p class="abstract">Arteriovenous malformations (AVM) are benign vascular anomalies prone to pain, bleeding, and progressive growth. Treatment is often difficult and relapse after therapy is common. AVM are mainly caused by somatic mosaicism with pathogenic variants of the RAS-MAPK pathway. However, a causative variant is not identified in all patients. Using ultra-deep next generation sequencing we identified novel somatic RIT1 indel variants in lesional tissue of three AVM patients. RIT1 - not previously implicated in AVM development - encodes a RAS-like protein that can modulate RAS-MAPK signaling. For biochemical characterization, we expressed RIT1 variants in HEK293T cells, which led to a strong increase in ERK1/2 phosphorylation. Endothelial-specific mosaic overexpression of the RIT1 indels in zebrafish embryos induced AVM formation, highlighting the functional importance in vascular development. Both ERK1/2 hyperactivation in vitro and AVM formation in vivo could be suppressed by pharmacological MEK inhibition. Targeted treatment with the MEK inhibitor trametinib led to a significant decrease in bleeding episodes and AVM size in one patient. Our findings expand the genetic spectrum of AVM by identifying RIT1 as a novel gene involved in AVM formation and pave the way for targeted treatment and clinical trials in patients with AVM.</p>
      </div>
    </div>
  </div>
</div>









<script src="/js/bundle.min.js" defer></script>



  </div>

  <footer class="post-footer">
    <ul class="post-tags">
    </ul>
  </footer>
</article>
    </main>
    
<footer class="footer">
    <span>&copy; 2023 <a href="https://trxiv.yorks0n.com">TRxiv2</a></span>
    <span>
        · Made by Yorkson
    </span>
</footer>
<a href="#top" aria-label="go to top" title="Go to Top (Alt + G)" class="top-link" id="top-link" accesskey="g">
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 12 6" fill="currentColor">
        <path d="M12 6H0l6-6z" />
    </svg>
</a>

<script>
    let menu = document.getElementById('menu')
    if (menu) {
        menu.scrollLeft = localStorage.getItem("menu-scroll-position");
        menu.onscroll = function () {
            localStorage.setItem("menu-scroll-position", menu.scrollLeft);
        }
    }

    document.querySelectorAll('a[href^="#"]').forEach(anchor => {
        anchor.addEventListener("click", function (e) {
            e.preventDefault();
            var id = this.getAttribute("href").substr(1);
            if (!window.matchMedia('(prefers-reduced-motion: reduce)').matches) {
                document.querySelector(`[id='${decodeURIComponent(id)}']`).scrollIntoView({
                    behavior: "smooth"
                });
            } else {
                document.querySelector(`[id='${decodeURIComponent(id)}']`).scrollIntoView();
            }
            if (id === "top") {
                history.replaceState(null, null, " ");
            } else {
                history.pushState(null, null, `#${id}`);
            }
        });
    });

</script>
<script>
    var mybutton = document.getElementById("top-link");
    window.onscroll = function () {
        if (document.body.scrollTop > 800 || document.documentElement.scrollTop > 800) {
            mybutton.style.visibility = "visible";
            mybutton.style.opacity = "1";
        } else {
            mybutton.style.visibility = "hidden";
            mybutton.style.opacity = "0";
        }
    };

</script>
<script>
    document.getElementById("theme-toggle").addEventListener("click", () => {
        if (document.body.className.includes("dark")) {
            document.body.classList.remove('dark');
            localStorage.setItem("pref-theme", 'light');
        } else {
            document.body.classList.add('dark');
            localStorage.setItem("pref-theme", 'dark');
        }
    })

</script>
</body>

</html>
